VFA
Values First Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.29M | Sell |
3,947
-4,166
| -51% | -$1.36M | 0.7% | 48 |
|
|
2025
Q1 | $2.19M | Sell |
8,113
-879
| -10% | -$237K | 1.28% | 16 |
|
|
2024
Q4 | $2.12M | Buy |
8,992
+202
| +2% | +$47.5K | 1.16% | 17 |
|
|
2024
Q3 | $2.42M | Buy |
8,790
+1,200
| +16% | +$330K | 1.31% | 15 |
|
|
2024
Q2 | $1.84M | Sell |
7,590
-148
| -2% | -$36K | 1.11% | 31 |
|
|
2024
Q1 | $1.16M | Buy |
7,738
+755
| +11% | +$113K | 0.68% | 45 |
|
|
2023
Q4 | $1.34M | Buy |
6,983
+476
| +7% | +$91.1K | 0.81% | 41 |
|
|
2023
Q3 | $1.15M | Sell |
6,507
-50
| -0.8% | -$8.85K | 0.74% | 42 |
|
|
2023
Q2 | $1.25M | Buy |
6,557
+146
| +2% | +$27.7K | 0.75% | 42 |
|
|
2023
Q1 | $1.28M | Buy |
6,411
+109
| +2% | +$21.8K | 0.82% | 35 |
|
|
2022
Q4 | $1.5M | Buy |
6,302
+35
| +0.6% | +$8.32K | 1.05% | 30 |
|
|
2022
Q3 | $1.25M | Buy |
6,267
+201
| +3% | +$40.2K | 0.9% | 35 |
|
|
2022
Q2 | $885K | Sell |
6,066
-430
| -7% | -$62.7K | 0.63% | 52 |
|
|
2022
Q1 | $1.06M | Buy |
6,496
+347
| +6% | +$56.7K | 0.67% | 49 |
|
|
2021
Q4 | $1.04M | Sell |
6,149
-368
| -6% | -$62.4K | 0.62% | 56 |
|
|
2021
Q3 | $1.23M | Buy |
6,517
+213
| +3% | +$40.2K | 0.8% | 43 |
|
|
2021
Q2 | $1.07M | Sell |
6,304
-130
| -2% | -$22K | 0.73% | 49 |
|
|
2021
Q1 | $908K | Buy |
6,434
+99
| +2% | +$14K | 0.67% | 52 |
|
|
2020
Q4 | $823K | Sell |
6,335
-199
| -3% | -$25.9K | 0.66% | 54 |
|
|
2020
Q3 | $951K | Buy |
6,534
+331
| +5% | +$48.2K | 0.87% | 45 |
|
|
2020
Q2 | $919K | Sell |
6,203
-146
| -2% | -$21.6K | 0.91% | 45 |
|
|
2020
Q1 | $691K | Buy |
6,349
+367
| +6% | +$39.9K | 0.83% | 45 |
|
|
2019
Q4 | $689K | Buy |
+5,982
| New | +$689K | 0.67% | 54 |
|